14 dec: Rias FY: Indtjeningen og udbyttet løftes
14 dec: Dong Energy sikrer sig partner til havmølleprojekt i USA
14-12-2016 13:43:46

Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine

Relateret indhold
26 jan - 
Bristol-Myers leverer svag indtjening og nedjusterer
17 jan - 
Tirsdagens aktier: Dong og Mærsk positive islæt i eller..
17 jan - 
Aktier/middag: Mærsk og Genmab i top mens markedet vent..
Relateret debat
25 feb - 
Der er flere år til, en færdig vaccine er k..
25 feb - 
Ja Hanne, det lader til at aktierne bliver udsolgt på m..
25 feb - 
Tak for endnu en fin opdatering 👍

COPENHAGEN, Denmark, December 14, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has completed enrollment of 400 subjects in a Phase 2 clinical study of MVA-BN® RSV, a novel, broad spectrum, vaccine candidate against RSV (respiratory syncytial virus).

The study is evaluating the safety and immunogenicity of different doses of MVA-BN RSV in healthy subjects aged 55 or older. Top-line results from the study are anticipated in mid-2017 and will provide essential information for subsequent, larger efficacy studies.

 

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: "We are very pleased to finalize enrollment in this study. Maintaining our pace of development in this highly underserved disease area is a key priority for Bavarian Nordic. We look forward to reporting data from this study, which will not only provide additional proof of concept for our multi-targeted approach, but will also help us to better understand the dosing requirements for patients as we progress to larger studies."

About MVA-BN RSV

MVA-BN RSV represents a new vaccine approach specifically designed to target five different RSV proteins to ensure a broad immune response against both RSV subtypes (A & B). Extensive preclinical studies have shown that MVA-BN RSV induces a balanced immune response comprised of both antibodies and T cells, in a similar fashion to the natural response to an RSV infection. These results were confirmed in a Phase 1 study in healthy adults, reported in May 2016, which showed that MVA-BN RSV significantly boosted antibodies and T cells against both RSV subtypes. The vaccine was well tolerated, with no unexpected or serious adverse reactions. The vast majority of events represented local and systemic reactions typical for vaccines.

About RSV

Respiratory syncytial virus, or RSV, is the most common cause of bronchiolitis and pneumonia in infants and a significant cause of respiratory illness in older adults, resulting in a high number of hospitalizations. RSV infections are responsible each year for a similar number of deaths as the flu in children up to age 14, as well as in the elderly population. It is estimated that more than 64 million people are infected globally each year, yet unlike the flu, there is no vaccine to prevent RSV, presenting a large unmet medical need and market opportunity.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

2016-12-14-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 775160.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 feb
BAVA
Tak for den dybe analyse, meget brugbart. Jeg har fluks solgt 8400 stk. på din fine anbefaling.   Af..
20
24 feb
BAVA
For pokker hvor er de ved at gøre klar til at kører stærk hen over sommeren - Hvis vi lige kikker på..
17
20 feb
BAVA
Der er såmænd nok ikke så mange herinde, der har en profession, der gør os til eskperter - og da sle..
14
23 feb
BAVA
Han havde nok påbegyndt tråden inden de 2 andre var oprettet,..det er jo trods alt noget af en tekst..
9
24 feb
BAVA
Endnu engang tak fordi du tager opdatere, og ja det er bare fedt. Udover de facts som du beskriver e..
8
20 feb
BAVA
  Jeg syntes det mdr for mdr ser bedre og bedre ud - markedet har en lidt anden mening - h..
8
22 feb
BAVA
6
21 feb
BAVA
Jeg vil heller være konservativ i det jeg tror - men kik lige selv på den pipeline på det som kommer..
6
23 feb
BAVA
Lad os nu lige se om der er nogle af analytikkerne som reagere på dette - fordelen ved RSV er at res..
4
23 feb
BAVA
Published: 16:20 CET 23-02-2017 /GlobeNewswire /Source: Bavarian Nordic A/S / : BAVA /ISIN: DK001599..
4

Rovsing mindsker driftsunderskud i første halvår og opjusterer

24-02-2017 16:36:15
Omsætningen i Rovsing, der har hovedkontor i Skovlunde ved København og blandt andet producerer testsystemer til satellitter og elektroniske produkter til rumin..

KORR. Genmab/Sydbank: Positiv anbefaling er godt nyt - og ventet

24-02-2017 14:04:12
(Korr: "uger" rettet til "måneder" i sjette afsnit)Det europæiske lægemiddelagenturs (EMA) komite for medicinske produkter for human anvendelse (CHMP) har givet..

Aktier/middag: Mærsk og Genmab i C20-bunden og dukkert til Rockwool

24-02-2017 11:44:51
Trods yderligere fremgang til ISS, der torsdag leverede et stærkt regnskab, ligger det danske aktiemarked fredag middag i et minus efter fald i aktier som Mærsk..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Bavarian Nordic A/S 283,00 1,1% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. februar 2017 20:06:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170217.2 - EUROWEB5 - 2017-02-26 20:06:43 - 2017-02-26 20:06:43 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x